<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085627</url>
  </required_header>
  <id_info>
    <org_study_id>2018-10-17</org_study_id>
    <nct_id>NCT04085627</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Valsartan / Amlodipine From Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland)</brief_title>
  <acronym>ABSVAFVATVAT</acronym>
  <official_title>Comparative Open-label,Randomized, Fasting/Fed, Single Dose, Three-way Crossover Bioequivalence Study of Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative randomized, single dose, three periods, three-way crossover open-label study to&#xD;
      determine the bioequivalence of Valsartan and Amlodipine Tablets (Hua yuan Pharmaceutical&#xD;
      LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG,&#xD;
      Switzerland).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Pharmacokinetic Parameters: Cmax, Area under cover (AUC0→t and AUC0→∞ ) .Secondary&#xD;
      Pharmacokinetic Parameters: tmax and t1/2. The method of judging bioequivalence of&#xD;
      three-cross-section repeating experiment design: first of all, the calculation of the SWR of&#xD;
      the AUC and Cmax, if SWR≥0.294, the use of RSABE analysis; if Swr&lt;0.294, the average&#xD;
      Bioequivalence analysis method with Non-scale (bioequivalence limit is 80%~125 %）.&#xD;
&#xD;
      A comprehensive final report will be issued upon the completion of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Anticipated">December 26, 2019</completion_date>
  <primary_completion_date type="Actual">November 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC parameters</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AE)s</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
    <description>Safety and tolerability parameters will include recording of AEs(blood biochemistry, urine routine examination, electrocardiograph, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
    <description>Vital sign measurement will include blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse rate</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
    <description>Vital sign measurement will include pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiration rate</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
    <description>Vital sign measurement will include respiration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ear temperature</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
    <description>Vital sign measurement will include ear temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete blood count</measure>
    <time_frame>Up to 96 hours post dose in each treatment period</time_frame>
    <description>Clinical laboratory tests will include CBC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg&amp; Amlodipine 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg&amp; Amlodipine 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan and Amlodipine Tablets</intervention_name>
    <description>1 tablet contains Valsartan 80mg&amp; Amlodipine 5mg</description>
    <arm_group_label>R Reference</arm_group_label>
    <arm_group_label>T Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or non-pregnant non-lactating female, age 18 to 45 years, including the&#xD;
             critical value.&#xD;
&#xD;
          -  Male weight ≥ 50kg, female weight ≥ 45kg, body mass index (BMI) between 19 and 28kg /&#xD;
             m2, including the critical value.&#xD;
&#xD;
          -  Good health, no heart, liver, kidney, digestive tract, nervous system, mental&#xD;
             disorders and metabolic disease history.&#xD;
&#xD;
          -  Sign informed consent prior to the test and fully understand the contents, process and&#xD;
             possible adverse reactions, and be able to communicate well with the researcher.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical trials in the 90 days prior to the trial, or other clinical trials&#xD;
             planned for the duration of the trial.&#xD;
&#xD;
          -  Underwent major surgery within 90 days of the trial or planned to undergo surgery&#xD;
             within 3 months of the trial.&#xD;
&#xD;
          -  Blood loss or blood donation over 300mL in the 90 days before the test.&#xD;
&#xD;
          -  Esophageal reflux, stomach bleeding or peptic ulcer disease in the 180 days prior to&#xD;
             the test, heartburn occurs more than once a week, or any surgical procedure that may&#xD;
             affect drug absorption (E.G. cholecystectomy).&#xD;
&#xD;
          -  Persons with specific allergies (asthma, urticaria, eczema, etc.) or allergies (such&#xD;
             as those who are allergic to two or more medications, food or pollen), or are known to&#xD;
             be allergic to the ingredients * or analogues of the drug.&#xD;
&#xD;
               -  The main components of the trial preparation: valsartan, benzene sulfonic acid&#xD;
                  amlodipine, microcrystalline cellulose, crosslinked povidone, crosslinked&#xD;
                  carboxymethyl cellulose sodium, silica, magnesium stearate, hydroxypropyl methyl&#xD;
                  cellulose, iron oxide yellow, polyethylene glycol, talc, Titanium dioxide;&#xD;
                  Reference Preparation main components: valsartan, amlodipine, microcrystalline&#xD;
                  cellulose, cross-linked povidone, silica, Magnesium stearate, hydroxypropyl&#xD;
                  methyl cellulose, iron oxide yellow, polyethylene glycol, talcum powder, Titanium&#xD;
                  Dioxide.&#xD;
&#xD;
          -  Use of any medication within 28 days of the trial, including prescription, over-&#xD;
             the-counter, and/or alternative medications (such as medicinal herbs, herbal&#xD;
             medicines, hemostasis and blood-activating plants or health supplements), and the use&#xD;
             of hormonal contraceptives or vaccines.&#xD;
&#xD;
          -  A history of psychotropic substance abuse.&#xD;
&#xD;
          -  Urine screening Positive.&#xD;
&#xD;
          -  The average daily smoking was over 3 in the 90 days prior to the trial, alcohol&#xD;
             consumption, women drinking more than 7 cups per week for 28 days or more than 14 cups&#xD;
             per week for men (1 cups of =150ml wine =360ml Beer =45ml spirits).&#xD;
&#xD;
          -  Alcohol expiratory test Positive.&#xD;
&#xD;
          -  Body temperature (ear Temperature) ≥37.5℃, breathing is obviously abnormal and the&#xD;
             researchers believe that it is not suitable to participate in the test, sitting&#xD;
             systolic pressure &gt;140mmhg or &lt;100mmhg, sitting diastolic pressure &gt;90mmhg or &lt;60mmhg,&#xD;
             sitting pulse 50 times/minute or &gt; 100 Times/minute.&#xD;
&#xD;
          -  Human immunodeficiency virus antibody (HIV-Ab), hepatitis B virus surface antigen&#xD;
             (HBsAg), hepatitis C virus antibody (HCV-Ab) or Treponema pallidum antibody (TP)&#xD;
             Positive.&#xD;
&#xD;
          -  Special dietary requirements, No uniform diet during the trial.&#xD;
&#xD;
          -  Subjects refused to comply with the drug before 48h banned caffeine, alcohol,&#xD;
             grapefruit beverages and food (including tea, chocolate, coffee, coke, etc.).&#xD;
&#xD;
          -  Participants with a companion refused to use effective contraceptive measures within&#xD;
             180 days of screening to the completion of the test, as detailed in Appendix 2.&#xD;
&#xD;
          -  Female subjects were tested positive for blood/urine pregnancy.&#xD;
&#xD;
          -  Persons with impaired renal function, or who have suffered from urinary system&#xD;
             disease.&#xD;
&#xD;
          -  A History of orthostatic hypotension.&#xD;
&#xD;
          -  fainting during venipuncture, dizzy blood and venous blood collection difficult&#xD;
             person.&#xD;
&#xD;
          -  The physical examination was obviously abnormal and the researchers found it&#xD;
             inappropriate to participate in the trial.&#xD;
&#xD;
          -  There was a significant abnormality in the ECG test and the researchers found it&#xD;
             inappropriate to Participate.&#xD;
&#xD;
          -  Blood biochemistry, blood routine, urine routine examination had the obvious&#xD;
             abnormality and the researcher thought that was not suitable to participate in the&#xD;
             experiment.&#xD;
&#xD;
          -  Subjects may not be able to complete this study or other researchers ' judgment for&#xD;
             other reasons. Note: the exclusion criteria in 1th, 2, 3, 4, 6, 9 in the time are from&#xD;
             the first 1 days before the administration of the Calculation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 8, 2019</last_update_submitted>
  <last_update_submitted_qc>September 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT04085627/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

